Abstract: Inflammatory and fibrotic events that drive chronic pancreatitis (CP) are likely orchestrated via signaling of soluble cytokines and chemokines systemically and within the pancreas. However, a comprehensive summary of the expression of such factors during CP has not been reported to date. This information is important given continued interest in targeting cytokines that influence CP pathogenesis. Reported data on the expression change of soluble immunomodulatory factors in human CP patients were identified via a literature search using a single search term. Thirty-one articles meeting the prespecified inclusion criteria were identified to generate a compiled data summary. Compiled data demonstrated up-regulation of several factors in the blood or pancreas microenvironment of CP patients. Nine factors were elevated in both compartments, including fractalkine, IFN-γ, interleukin 1β, IL-6, IL-8, macrophage inhibitory cytokine 1, neutrophil gelatinase-associated lipocalin, transforming growth factor β, and tumor necrosis factor α. Most up-regulated factors could be classified into one of several functional groups, including inflammation, chemotaxis, angiogenesis, bone remodeling, extracellular matrix remodeling, and pain. After further validation, these factors may be used as biomarkers for disease diagnosis and identification of comorbidities, or as potential therapeutic targets.
C hronic pancreatitis (CP) is a severe inflammatory condition with a prevalence of approximately 50 per 100,000 people. 1, 2 Symptoms include abdominal pain, nausea, and maldigestion due to inflammation and fibrosis of the pancreas. Because no curative or preventative therapies are available, parenchymal damage often progresses to irreversible endocrine and exocrine insufficiency. 3 In addition, those with CP have an increased risk for developing pancreatic cancer compared to those without disease. [4] [5] [6] [7] Thus, enhanced understanding and novel treatment strategies are desperately needed.
Factors that contribute to the development of CP are varied and multifactorial, including both lifestyle and genetic components. 8, 9 Common among all etiologies is the damaging role of proinflammatory and profibrotic factors in promoting disease progression. Accordingly, limiting the fibroinflammatory response during CP could have a significant effect on the course of disease.
Although chronic inflammation is a hallmark of CP and contributes to much of the associated damage, our understanding of immune involvement remains limited. Analysis of human tissue reveals robust macrophage infiltration into the pancreata of CP patients in addition to the presence of CD4 + and CD8 + T-cell populations. 10, 11 Findings from animal models support these observations, demonstrating a role for both innate and adaptive immune cell populations in the pathogenesis of CP. [12] [13] [14] Accordingly, many features of the inflamed pancreas are influenced by the profile of cytokines and chemokines present, which control the infiltration, survival, and differentiation of immune cells. 15 Soluble factors arise from multiple compartments including innate and adaptive immune populations as well as parenchymal cells and local fibroblasts termed pancreatic stellate cells.
Although dysregulated expression of soluble immunomodulatory factors is reported consistently in patients and animal models of CP, it is surprising that few studies have attempted to neutralize these soluble factors therapeutically, an observation that is true both clinically and preclinically. [15] [16] [17] [18] [19] In murine models, studies have demonstrated the pathologic role of interleukin (IL-) 6 during acute pancreatitis and have shown therapeutic benefit of IL-6 blockade. 20, 21 Additional animal studies suggest a role for transforming growth factor β (TGF-β), tumor necrosis factor α (TNF-α), and CXCL10 in promoting progression to CP. [22] [23] [24] Most efforts to confirm and target these and other soluble factors have been performed in animal models with diverse etiologies and are largely focused on acute pancreatitis. Data from human samples have also been derived primarily from patients with the acute condition, which displays marked differences in cytokine profiles compared with CP. As a result, data specific to human CP are lacking. With few in vivo studies and no current clinical trials targeting soluble mediators in CP, there are few functional data to aid in the prioritization of cytokine targets.
Accordingly, the comprehensive changes in immunomodulatory factor expression during CP and the ability to target these factors remain poorly understood. To address this gap in knowledge, we performed a literature search to identify articles that characterize the expression of 1 or more soluble factors in human patients with CP as compared with control participants. We have compiled and analyzed these data to enhance our understanding of changes in the expression of immunomodulatory factors during CP. controls. To accomplish this, we performed a literature search of PubMed for articles published between January 1, 1990, and July 1, 2016, using a focused search strategy (cytokines[MeSH] AND chronic pancreatitis [MeSH] ) to reveal 126 results (Fig. 1) . From these articles, we reviewed English and non-English articles that contained human data from CP participants compared with healthy controls. Diagnostic criteria used to define CP varied by article; however, in general, this relied on a combination of a consistent clinical syndrome, imaging (computed tomography, magnetic resonance imaging, and/or endoscopic ultrasound), and, occasionally, pancreatic function testing. Compiled data from these articles illustrate changes in expression of soluble factors systemically, in serum or plasma (Table 1) , and locally, in pancreatic tissue and pancreatic fluid ( Table 2 ). The expression levels of factors were analyzed using a variety of techniques, including enzyme-linked immunosorbent assay, Western blot, immunohistochemistry, and polymerase chain reaction.
RESULTS

Summary of Findings From Literature Search
Our literature search specifications and inclusion criteria resulted in a total of 36 articles included in this review. Within these articles, 90 unique soluble factors were assessed in blood, pancreatic juice, or pancreatic tissue of human subjects with CP compared with controls. Seventy-one of these 90 factors were mentioned by only a single article. For factors examined by more than 1 article, the direction of expression change was generally concordant between articles, except in the case of CXCL10 and CCL3, which were cited as both up-and down-regulated by 2 independent studies. Soluble factors concordantly identified as upregulated by multiple references include TNF-α, IL-6, TGF-β, IL-1β, fractalkine, matrix metalloproteinase (MMP)-9, interferon (IFN)-γ, and IL-8 in systemic analyses and IL-6, fractalkine, IL-8, and the fractalkine receptor (CX3CR1) in the local environment. Overall, regardless of citation frequency, 24 factors were upregulated in serum and 32 in local pancreatic tissue. Of these, 9 were up-regulated both systemically in blood and locally in pancreatic tissue (Fig. 2) .
Several factors were found to be down-regulated in CP compared with controls. In the blood, these included IL-10, insulin, leptin, platelet factor 4, and vitamin D (25-hydroxyvitamin D [25OHD]). Within the pancreatic microenvironment, a single article cited decreases in CXCL10, EGF, eotaxin, IL-15, IL-1α, IL-3, MIP-1α, and platelet-derived growth factor (PDGF) levels in pancreatic juice obtained during endoscopic pancreatic function testing. 42 
Patterns of Immunomodulatory Factor Expression
Of the soluble factors up-regulated in CP samples, most could be organized into 1 of the following functional groups associated with CP pathogenesis: inflammation, chemotaxis, angiogenesis, bone remodeling, extracellular matrix remodeling, and pain (Table 3 ). In particular, factors involved in inflammation were prominently up-regulated in CP. In the local environment, a large number of chemokines were observed, whereas in the blood, most soluble factors were proinflammatory cytokines.
These up-regulated factors were subsequently categorized by their ability to influence differentiation of T helper cell (T H ) subsets (Fig. 3 ). This analysis demonstrated that patients with CP display an up-regulated cytokine profile consistent with the differentiation of T H 1, T H 17, and regulatory T-cell populations.
DISCUSSION
To our knowledge, this review is the first study to systematically analyze available data concerning immunomodulatory factor expression in patients with CP. Factors found to be up-or down-regulated by multiple independent studies offer increased confidence in the validity of these findings. These consistently up-regulated proteins, including TNF-α, IL-6, TGF-β, IL-1β, fractalkine, MMP-9, IFN-γ, and IL-8 in the serum and IL-6, fractalkine, IL-8, and fractalkine-R in the local environment are likely to play an important role in disease progression or may serve as immunologic biomarkers in CP. Similarly, several factors that were down-regulated align with known clinical manifestations of disease. For example, decreased circulating insulin and leptin are likely the result of progressive pancreatic dysfunction during the course of disease. Chronic pancreatitis-associated exocrine insufficiency commonly results in fat malabsorption and fatsoluble vitamin deficiencies, notably 25OHD. 60 Accordingly, our literature review noted a reduction in levels of circulating vitamin D in CP patients. Such findings increase confidence in the validity of the data and its relevance to CP disease progression.
Up-regulation of proinflammatory and chemotactic molecules was particularly evident in our analysis. The presence of elevated proangiogenic factors is also consistent with data that show increased angiogenesis during CP and PDAC and its association with KRAS mutation status. [61] [62] [63] Similarly, changes in factors associated with bone remodeling are anticipated on the basis of clinical observations demonstrating high rates of bone remodeling, specifically bone loss, in the CP patient population, with approximately 65% experiencing either osteoporosis or osteopenia. [64] [65] [66] In addition, up-regulated factors involved in extracellular matrix (ECM) remodeling mirror histological analysis demonstrating increased collagens and fibronectin with reduced fibril organization in fibrotic and normal tissue sections from human CP pancreatic tissue. 67 Pancreatic stellate cells, which secrete MMPs, tissue inhibitor of MMPs (TIMPs), and collagen in response to inflammatory cytokines, are known to contribute to pathogenic ECM alterations. [68] [69] [70] Several soluble factors identified in this review are also involved in pain, which has a pronounced role in the clinical course of CP. 71, 72 Abdominal pain is present in up to 90% of CP cases and is the primary cause of hospitalization. Poulsen et al 73 have previously summarized the evidence for abnormal pain processing in CP, which includes nerve sensitization and altered pain control systems. Overall, the prevalence of factors involved in pain, ECM remodeling, bone turnover, angiogenesis, 
Immunomodulatory Factors in Chronic Pancreatitis inflammation, and chemotaxis is consistent with clinical manifestations of observed in CP patients. Soluble factors up-regulated in CP were also organized on the basis of their immune activity, revealing increased T H 1-and T H 17-associated signaling molecules. These data are in agreement with prior mechanistic studies, which suggest a role for these cells and cytokines in pancreatic inflammation as it relates to either CP or pancreatic cancer. [74] [75] [76] [77] Imbalances between T H 17 and regulatory T-cell populations and their cytokines have also been implicated in the development of inflammation, autoimmunity, tumorigenesis, and others. 78, 79 The influence of these T-cell subsets and polarizing cytokines within the pancreatic microenvironment deserves further investigation to delineate the role of each in CP progression.
We are hopeful that enhanced understanding of pathogenic cytokine expression in CP, facilitated by this review, will catalyze future efforts to generate novel treatment strategies for this patient population. Despite increases in proinflammatory cytokines such as IL-6 and TNF-α, few preclinical in vivo studies and no clinical Tissue, juice 14-3-3-zeta = trials have been attempted to target these particular cytokines in CP. In theory, neutralization of these soluble factors or inhibition of downstream pathways has the potential to block key signaling nodes in pathogenic inflammatory and fibrotic processes. In other inflammatory conditions, agents such as tocilizumab (anti-IL-6R) and daclizumab (anti-CD25) have shown efficacy in the treatment of rheumatoid arthritis and multiple sclerosis, respectively. 80, 81 Data from this study may also be used to support development of advanced mathematical models that simulate cytokine interactions on cells within the pancreas microenvironment. Similar theoretical studies have been conducted by our group for pancreatic cancer and are currently underway as an extension into CP. 82 Finally, these data may also aid efforts in implementing new diagnostic or prognostic strategies in CP. As early diagnosis of CP remains difficult, the addition of one or multiple soluble factors from the analysis of blood or pancreatic fluid, in combination with current diagnostic methods, has the potential to increase diagnostic accuracy. Earlier diagnosis will be critical as therapeutic options become available to facilitate timely intervention and prevent progressive organ dysfunction.
In theory, comorbidities of CP, including pancreatic cancer, diabetes, and metabolic bone disease, 83 may be identified earlier via periodic screening with a panel of select soluble factors associated with each comorbidity. For instance, because almost twothirds of CP patients develop metabolic bone disease, groups of validated cytokines associated with bone turnover, as shown in Table 3 , may be used in future studies to monitor risk of bone disease in patients. 66 Such practices have the potential to greatly expedite diagnosis and intervention for the most common complications.
Despite the benefits of this comprehensive literature summary, there are challenges in interpreting such data that deserve mention. First, the specific soluble factors included in this review were not stochastically generated but were instead chosen to be analyzed in each of the articles reviewed. Accordingly, soluble messengers that have already been implicated in CP progression or that are commonly involved in fibroinflammatory conditions are more likely to be studied in the context of CP and may thus be overrepresented in a way not related to their importance or abundance during disease. However, congruent findings by independent sources serve to increase overall confidence in the direction of expression change for these factors. In addition, our study was focused on expression of factors in CP rather than acute pancreatitis, a condition that may have a distinct profile of inflammatory mediators. 17 Second, it is also important to consider the diverse nature of CP etiologies when interpreting these data. The effect of etiology on immune profiles during CP is currently unclear. Accordingly, it is possible that each etiology (including toxic-metabolic, idiopathic, genetic, autoimmune, recurrent and severe acute pancreatitis, or obstructive) may require an independent study to further understand the nuances of disease progression and to identify differences in potential therapeutic targets. 84 In addition, patient characteristics including age, sex, and stage of bFGF/FGF2/FGF-β indicates basic fibroblast growth factor; EGF, epidermal growth factor; Flt-3 L, fms-related tyrosine kinase 3 ligand; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte macrophage colony-stimulating factor; GRO, growth related oncogene; IAM1, alpha-amylase inhibitor BMAI-1; MIC-1, macrophage inhibitory cytokine 1; NGAL/LCN2, neutrophil gelatinase-associated lipocalin; VEGF, vascular endothelial growth factor. CP may affect the expression of soluble factors and should be considered in future studies.
This data summary will be useful for understanding the comprehensive changes associated with CP and identifying cytokines and chemokines of interest for continued investigation as diagnostic or therapeutic candidates. 
